Significant ETF Withdrawals for UVIX and SYNB
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 17 2025
0mins
Should l Buy ABBV?
Source: NASDAQ.COM
ETF Outflow Details: The Putnam BioRevolution ETF experienced the largest outflow, losing 50,000 units, which is a 40.0% decline in outstanding units compared to the previous week.
Market Performance: In morning trading, Thermo Fisher Scientific saw a slight decrease of about 0.3%, while Abbvie experienced a modest increase of approximately 0.9%.
Video Content: A video segment discusses significant ETF outflows, specifically mentioning UVIX and SYNB.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 208.160
Low
223.00
Averages
252.00
High
289.00
Current: 208.160
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Surprises with Strong Q1 Earnings, Boosting Stock
- Significant Revenue Growth: AbbVie's Q1 revenue reached $15 billion, marking a 12.4% year-over-year increase and surpassing the expected $14.7 billion, showcasing the company's strong performance in immunology and boosting investor confidence.
- Strong Immunology Business: Sales of Skyrizi and Rinvoq exceeded management's expectations, with AbbVie now projecting combined revenues of over $31 billion for these drugs in 2023, four years ahead of the previous 2027 target, reflecting the company's competitive edge in the market.
- Potential Expansion Opportunities: Rinvoq is awaiting approval for alopecia areata treatment, while Skyrizi could gain a new indication for Crohn's disease, which will further drive sales growth and enhance AbbVie's market position.
- Long-Term Growth Outlook: AbbVie has raised its earnings per share guidance for 2026, and with its strong product lineup and robust dividend policy, the company remains an attractive investment despite a 10% decline in stock price year-to-date.
See More
AbbVie Presents New Data at Digestive Disease Week 2026
- Research Presentation: AbbVie showcased 18 abstracts at the 2026 Digestive Disease Week, highlighting long-term efficacy data for SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, reinforcing its leadership in gastroenterology.
- Clinical Data Support: The studies indicate a low switch rate for SKYRIZI among Crohn's disease patients and a significant reduction in hospitalization rates after switching to RINVOQ, providing critical evidence for treatment decisions.
- Quality of Life Improvement: SKYRIZI has demonstrated improvements in health-related quality of life for Crohn's disease patients, with year-one results from the ASPIRE-CD study showing significant symptom relief, indicating its clinical application potential.
- FDA Application Progress: On April 27, 2026, AbbVie submitted an application to the FDA seeking approval for SKYRIZI's subcutaneous induction treatment in adult patients with Crohn's disease, which, if approved, will further expand its market share.
See More
Apple, Amazon, and TSMC Deliver Earnings Triple Plays
- Earnings Highlights: Apple, Amazon, and TSMC have all achieved a 'triple play' this quarter, delivering growth in earnings, revenue, and guidance, which underscores strong market demand and business resilience, further solidifying their leadership positions in their respective industries.
- Market Reaction: Investors reacted positively to the earnings reports from these three companies, driving stock prices higher, which reflects a renewed confidence in tech stocks and may attract more capital inflows into the technology sector.
- Industry Impact: The robust performance of these companies not only enhances their market valuations but may also lead to upward revisions in earnings expectations for other tech firms, creating a virtuous cycle that could further drive the recovery of the entire industry.
- Future Outlook: As the global economy gradually recovers, the success stories of Apple, Amazon, and TSMC may inspire other companies to adopt similar growth strategies, fostering innovation and investment that drive long-term growth.
See More
Three High-Yield Stocks for Monthly Dividends
- AbbVie's Strong Financials: AbbVie, with a market cap of approximately $370 billion, generated over $61 billion in revenue last year and $20 billion in operating income, demonstrating its ability to grow despite patent expirations, while its 3.3% dividend yield significantly exceeds the S&P 500 average of 1.1%.
- Medtronic's Stability: Medtronic, valued at $101 billion, reported a 9% revenue increase in its latest quarter, with free cash flow of $5.4 billion easily covering its $3.6 billion annual dividend payout, resulting in a 3.6% yield, making it an ideal choice for income-focused investors.
- Enbridge's Consistent Growth: Enbridge, with a market cap of $119 billion, has raised its dividend for 31 consecutive years, with a recent 3% increase, yielding 5.2%, the highest among the listed stocks, and despite a payout ratio over 100%, its distributable cash flow indicates strong financial health.
- Diversified Investment Strategy: By investing in AbbVie, Medtronic, and Enbridge, investors can achieve monthly cash flow, leveraging the different dividend payment schedules of these companies to enhance the stability of their investment portfolio.
See More
Analysis of High-Yield Stock Investment Strategies
- AbbVie's Financial Strength: AbbVie, with a market cap of approximately $370 billion, generated over $61 billion in revenue and $20 billion in operating income last year despite patent expirations, ensuring a safe 3.3% dividend yield backed by robust financials.
- Medtronic's Stable Growth: Medtronic's revenue rose by 9% in the latest quarter, exceeding guidance, with free cash flow of $5.4 billion over the past 12 months, significantly surpassing its $3.6 billion annual dividend payout, offering a 3.6% yield ideal for income-focused investors.
- Enbridge's Consistent Dividends: Enbridge has increased its dividend for 31 consecutive years, with a recent 3% hike bringing its yield to 5.2%; despite a payout ratio over 100%, its distributable cash flow assessment indicates strong financial health, making it a solid long-term investment.
- Diversified Dividend Portfolio: By investing in stocks like AbbVie, Medtronic, and Enbridge, which pay dividends at different times, investors can achieve stable monthly cash flow, enhancing portfolio income, particularly beneficial for retirees or those seeking to boost their earnings.
See More
Three Dividend Stocks Worth Investing In
- AbbVie's Growth Potential: AbbVie successfully expanded its product portfolio and added Botox through a $63 billion acquisition of Allergan, and despite losing patent protection for its flagship drug Humira, the company still achieved over 12% revenue growth in Q1 2026, demonstrating strong growth potential.
- Verizon's Acquisition Advantage: With a dividend yield of 5.9%, Verizon attracts investors, and despite a 17% stock price increase this year, its forward P/E ratio is only 10; the acquisition of Frontier is expected to enhance its fiber access capabilities, further boosting future growth prospects.
- Canadian Natural Resources' Inflation Hedge: Canadian Natural Resources has seen its stock price rise 40% this year amid rising oil prices, and while its dividend yield stands at 3.8%, its forward P/E remains below 14, indicating strong profitability even in economic uncertainty.
- Sustained Dividend Growth: Canadian Natural Resources has raised its dividend for 26 consecutive years, averaging a compounded annual growth rate of about 20%, maintaining stable dividend payments even during periods of low oil prices, showcasing its appeal as a high-dividend stock.
See More
AbbVie Surprises with Strong Q1 Earnings, Boosting Stock
- Significant Revenue Growth: AbbVie's Q1 revenue reached $15 billion, marking a 12.4% year-over-year increase and surpassing the expected $14.7 billion, showcasing the company's strong performance in immunology and boosting investor confidence.
- Strong Immunology Business: Sales of Skyrizi and Rinvoq exceeded management's expectations, with AbbVie now projecting combined revenues of over $31 billion for these drugs in 2023, four years ahead of the previous 2027 target, reflecting the company's competitive edge in the market.
- Potential Expansion Opportunities: Rinvoq is awaiting approval for alopecia areata treatment, while Skyrizi could gain a new indication for Crohn's disease, which will further drive sales growth and enhance AbbVie's market position.
- Long-Term Growth Outlook: AbbVie has raised its earnings per share guidance for 2026, and with its strong product lineup and robust dividend policy, the company remains an attractive investment despite a 10% decline in stock price year-to-date.
See More
AbbVie Presents New Data at Digestive Disease Week 2026
- Research Presentation: AbbVie showcased 18 abstracts at the 2026 Digestive Disease Week, highlighting long-term efficacy data for SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, reinforcing its leadership in gastroenterology.
- Clinical Data Support: The studies indicate a low switch rate for SKYRIZI among Crohn's disease patients and a significant reduction in hospitalization rates after switching to RINVOQ, providing critical evidence for treatment decisions.
- Quality of Life Improvement: SKYRIZI has demonstrated improvements in health-related quality of life for Crohn's disease patients, with year-one results from the ASPIRE-CD study showing significant symptom relief, indicating its clinical application potential.
- FDA Application Progress: On April 27, 2026, AbbVie submitted an application to the FDA seeking approval for SKYRIZI's subcutaneous induction treatment in adult patients with Crohn's disease, which, if approved, will further expand its market share.
See More
Apple, Amazon, and TSMC Deliver Earnings Triple Plays
- Earnings Highlights: Apple, Amazon, and TSMC have all achieved a 'triple play' this quarter, delivering growth in earnings, revenue, and guidance, which underscores strong market demand and business resilience, further solidifying their leadership positions in their respective industries.
- Market Reaction: Investors reacted positively to the earnings reports from these three companies, driving stock prices higher, which reflects a renewed confidence in tech stocks and may attract more capital inflows into the technology sector.
- Industry Impact: The robust performance of these companies not only enhances their market valuations but may also lead to upward revisions in earnings expectations for other tech firms, creating a virtuous cycle that could further drive the recovery of the entire industry.
- Future Outlook: As the global economy gradually recovers, the success stories of Apple, Amazon, and TSMC may inspire other companies to adopt similar growth strategies, fostering innovation and investment that drive long-term growth.
See More
Three High-Yield Stocks for Monthly Dividends
- AbbVie's Strong Financials: AbbVie, with a market cap of approximately $370 billion, generated over $61 billion in revenue last year and $20 billion in operating income, demonstrating its ability to grow despite patent expirations, while its 3.3% dividend yield significantly exceeds the S&P 500 average of 1.1%.
- Medtronic's Stability: Medtronic, valued at $101 billion, reported a 9% revenue increase in its latest quarter, with free cash flow of $5.4 billion easily covering its $3.6 billion annual dividend payout, resulting in a 3.6% yield, making it an ideal choice for income-focused investors.
- Enbridge's Consistent Growth: Enbridge, with a market cap of $119 billion, has raised its dividend for 31 consecutive years, with a recent 3% increase, yielding 5.2%, the highest among the listed stocks, and despite a payout ratio over 100%, its distributable cash flow indicates strong financial health.
- Diversified Investment Strategy: By investing in AbbVie, Medtronic, and Enbridge, investors can achieve monthly cash flow, leveraging the different dividend payment schedules of these companies to enhance the stability of their investment portfolio.
See More
Analysis of High-Yield Stock Investment Strategies
- AbbVie's Financial Strength: AbbVie, with a market cap of approximately $370 billion, generated over $61 billion in revenue and $20 billion in operating income last year despite patent expirations, ensuring a safe 3.3% dividend yield backed by robust financials.
- Medtronic's Stable Growth: Medtronic's revenue rose by 9% in the latest quarter, exceeding guidance, with free cash flow of $5.4 billion over the past 12 months, significantly surpassing its $3.6 billion annual dividend payout, offering a 3.6% yield ideal for income-focused investors.
- Enbridge's Consistent Dividends: Enbridge has increased its dividend for 31 consecutive years, with a recent 3% hike bringing its yield to 5.2%; despite a payout ratio over 100%, its distributable cash flow assessment indicates strong financial health, making it a solid long-term investment.
- Diversified Dividend Portfolio: By investing in stocks like AbbVie, Medtronic, and Enbridge, which pay dividends at different times, investors can achieve stable monthly cash flow, enhancing portfolio income, particularly beneficial for retirees or those seeking to boost their earnings.
See More
Three Dividend Stocks Worth Investing In
- AbbVie's Growth Potential: AbbVie successfully expanded its product portfolio and added Botox through a $63 billion acquisition of Allergan, and despite losing patent protection for its flagship drug Humira, the company still achieved over 12% revenue growth in Q1 2026, demonstrating strong growth potential.
- Verizon's Acquisition Advantage: With a dividend yield of 5.9%, Verizon attracts investors, and despite a 17% stock price increase this year, its forward P/E ratio is only 10; the acquisition of Frontier is expected to enhance its fiber access capabilities, further boosting future growth prospects.
- Canadian Natural Resources' Inflation Hedge: Canadian Natural Resources has seen its stock price rise 40% this year amid rising oil prices, and while its dividend yield stands at 3.8%, its forward P/E remains below 14, indicating strong profitability even in economic uncertainty.
- Sustained Dividend Growth: Canadian Natural Resources has raised its dividend for 26 consecutive years, averaging a compounded annual growth rate of about 20%, maintaining stable dividend payments even during periods of low oil prices, showcasing its appeal as a high-dividend stock.
See More
